Hepatitis D: Thirty years after  by Rizzetto, Mario
www.elsevier.com/locate/jhep
Journal of Hepatology 50 (2009) 1043–1050Review
Hepatitis D: Thirty years afterq
Mario Rizzetto*
Division of Gastroenterology, Molinette – University of Turin, Corso Bramante, Turin 10126, ItalyThe key to the discovery of the Hepatitis D Virus (HDV) was the description in Turin, Italy in the mid-1970s of the delta
antigen and antibody in carriers of the hepatitis B surface antigen. The new antigen was ﬁrst thought to be a marker of the
Hepatitis B Virus (HBV) and in view of its intricate true nature, it would have possibly died away as another odd antigenic
subtype of HBV, like many that were described in the 1970s. Fortunately, instead, a collaboration started in 1978 between
the Turin group, and the National Institute of Health and Georgetown University in the US. With American facilities and
expertise this collaboration led just a year later, in 1979, to the unfolding of an unexpected and amazing chapter in virol-
ogy. Experiments in chimpanzees demonstrated that the delta antigen was not a component of the HBV but of a separate
defective virus requiring HBV for its infection; it was named the hepatitis D virus to conform to the nomenclature of hep-
atitis viruses and classiﬁed within the genus Deltavirus. The animal experiments were also seminal in proposing to future
clinical interpretation, the paradigm of a pathogenic infection (hepatitis D), that could develop only in HBV-infected
patients, was mainly transmitted by superinfection of HDV on chronic HBV carriers and had the ability to strongly inhibit
the helper HBV. The discovery of the HDV has driven three directions of further research:(1) The understanding of the replicative and infectious mechanisms of the HDV.
(2) The assessment of its epidemiological and medical impact.
(3) The search for a therapy for chronic hepatitis D (CHD).This review summarizes the progress achieved in each ﬁeld of research in the thirty years that have passed since the dis-
covery of HDV.
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The genetic structure of the new virus appears rudi-
mentary at ﬁrst glance. The HD virion is a hybrid parti-
cle made up of the HD-Antigen (HD-Ag) and an RNA
species enclosed within a HBsAg coat derived from
HBV [1–3]. The virion contains a circular minute
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In the liver, the corresponding antigenomic circular
strand of positive polarity contains only one open read-
ing frame; this encodes the HD-Ag, the sole known pro-
tein of HDV, through the transcription of a 0.8 Kb
messenger RNA. The very measure of the genome size
indicated that HDV was not a conventional virus, as it
was distinctly smaller than all known animal viruses
[3,4]. Its size, and the folded RNA loop, were instead
similar to the size and structure of the RNA viroids of
higher plants; this ﬁrst suggested that HDV may have
originated from the plant rather than the animal world.
A second unique feature of HDV was the recognition
in 1989 that both the genomic and antigenomic strands
contained a ribozyme, a RNA segment of less than 100Published by Elsevier B.V. All rights reserved.
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able to self-cleave and self-ligate the circular HDV gen-
ome [5]. The HDV ribozymes have been crystallized [6]
and shown to catalyse cleavage of the HDV–RNA back-
bone with a rate of enhancement of 106- to 107-fold over
the uncatalyzed rate. They use several catalytic strategies
including the use of metal ions [7], intrinsic binding
energy and acid-base catalysis under physiological con-
ditions; the latter ability appears to be unique among
ribozymes [8]. Ribozymes are also present in viroids
and this was taken as further evidence to support an ori-
gin of HDV [9] from plants. However, viroids do not
code for protein and the structure of the ‘‘hammerhead”
ribozymes described in plant viruses is diﬀerent from the
HDV ribozymes, indicating that the catalytic domain of
HDV–RNA represents a diﬀerent ribozyme motif. More
intriguing, the ﬁnding that the CPEB3 ribozyme, a con-
served mammalian sequence residing in an intron of the
CPEB3 gene, is structurally and biochemically related to
the HDV ribozyme, suggests that HDV could derive
from the human trascriptome and may have evolved in
modern protein-dominated organisms rather than from
an ancestral RNA world [10]. Alternatively, human
HDV may have evolved from a viroid-like satellite
RNA of smaller original size, that acquired the RNA
encoding the HD-Ag and the ribozyme through recom-
bination with the human transcriptome [11].
The dilemma confronting early research on HDV was
how this virus could replicate; its minute genome coded
only for the HD-Ag and could not possibly code for any
of the complex enzymatic functions required for inde-
pendent replication. It was intuitive that HDV exploited
HBV and cellular functions, but what were these func-
tions and what role did the HDV play in the replication
process? Both questions have been answered in the last
30 years by the discovery of a surprisingly articulate
sequence of cellular and viral interactions leading to
HDV synthesis [12,13].
Crucial to the understanding of the respective role of
HBV and host cells was the report by Dr. Fu and Dr.
Taylor in 1993 [14] that hepatocytes nuclear extracts
were able to replicate faithfully the whole genomic and
antigenomic strand of HDV without any extraneous fac-
tor. The conclusion that HDV replication can proceed in
host cells in the absence of HBV proteins was conﬁrmed
by in vitro and in vivo transfection experiments; the ﬁrst
have shown that cDNA constructs of HDV induce gen-
ome replication when transfected into cultured cells [15],
the second that DNA copies of the HDV–RNA and of
the RNA itself injected into the tail vein of mice elicit
typical HDV replication with a transient expression of
HDV in several tissues of the rodent [16], besides the
liver. Therefore, mammalian cells can autonomously
support eﬃcient HBV replication. Avian cells do not
[17]; however, the fusion of mammalian to avian cells
rescues HDV synthesis, suggesting that avian cells lackfactors permissive to HDV replication that are restored
by mammalian cells.
Clearly, HDV needs HBV only to borrow the HBsAg
capsid whereby it attaches to hepatocytes and propa-
gates infection [18]. Within cells, HDV–RNA is associ-
ated with multiple copies of the HD proteins to
assemble into a ribonucleoprotein complex, which is
exported by the HBV envelope through the budding into
the lumen of a pre-Golgi compartment before being
secreted [18]. Though the small HBsAg alone can pack-
age the HDV ribonucleoprotein and assemble into viri-
ons [19], the large HBsAg protein bearing in S1 a
receptor to cells, is required to confer infectivity [20,21].
The HBsAg coat is not exclusive, as HDV can coat
also within the woodchuck hepatitis virus (WHV) sur-
face antigen and in vivo HDV has been passed from
chimpanzees to the rodent [4]. However, in apparent
contradiction to the in vivo transmission of primate
HDV to woodchucks, woodchuck-HDV was reported
to infect cultured primary woodchuck hepatocytes as
well as cultures of primary human hepatocytes, but
human HDV could not infect woodchuck hepatocytes
[22]; the diﬀerent host-range speciﬁcities seems deter-
mined by the diﬀerent recognition of WHV and HBV
Pre S1 proteins on human hepatocytes.
Conventional RNA viruses undergo replication by a
virus encoded RNA-dependent RNA-polymerase which
replicates the viral genome; they cannot use cellular
RNA-polymerases, as these accept only DNA tem-
plates. Hepatitis D virus does not possess any polymer-
ase, therefore, the next enigma was how it replicated in
the host. The explanation is that host RNA polymerase
II (Pol II), is deceived by HDV and becomes redirected
to read and copy its RNA. This was conﬁrmed by tran-
scriptional run-on experiments which have demon-
strated inhibition of viral synthesis after the addition
of low-dose amanitin [23], a toxin that selectively blocks
the accumulation of RNA Pol II transcripts. Presum-
ably the rod-like conformation of the viral RNA is rec-
ognized as double-stranded DNA for RNA Pol II
binding. Immunoprecipitation experiments using block-
ing monoclonal antibodies to RNA Pol II [24] have
shown that human RNA Pol II binds directly to the ter-
minal stem-loop regions of HDV–RNA and the interac-
tions of the HD-Ag with the RNA Pol II clamp, a
mobile structure that holds DNA and RNA in place,
may facilitate the unusual RNA synthesis [25]. Once
redirected to copy HDV–RNA, RNA Pol II carries
out unchecked its transcriptional activity, elongating a
multimeric linear transcript of either the genome or
the antigenome over the viral RNA circular template
of the other; this elementary double-rolling circle mech-
anism of replication is unknown to animal viruses but
operative in viroids [13].
The last step requires the rearrangement of the linear
multimeric strand into genomic and antigenomic HDV–
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zymes ﬁrst cleave the redundant transcription product
into a genomic/antigenomic size monomer and then
ligate the linear monomer into the infectious circular
form.
The intricate RNA-cellular interactions are only part
of the replicative story of HDV. Crucial and incredibly
complex for such a small molecule are also the functions
of the HD-Ag. The HD-Ag contains several functional
domains [26]; a coiled-coil domain facilitates protein–
protein interactions [27], a bipartite nuclear-localization
signal drives the HD proteins to the nucleus [28], an
oligomerization domain and two arginine rich motifs
support the binding to the RNA. It is edited by a cellular
double-stranded adenine-deaminase into a small HD-Ag
(SHD-Ag, 195 amino acid residues) and a large HD-Ag
(LHD-Ag, 214 amino acid residues), the ﬁrst promoting
replication, the second virion assembly [29]. Many other
functions of the HD-Ag isoforms have been recognized
and added to the list in the last years [12,13,30].
The dilemma is again how the two small HDV pro-
teins can escort the HDV genome through diﬀerent cel-
lular compartments and become involved in the diﬀerent
steps of replication, transcription and formation of
progeny virions. The answer is that the biological activ-
ities of the HD-Ag depend on a host of ordered protein–
protein interactions regulated by post-translational
modiﬁcations of the HD-Ag [31]; as a one gene–genome
the HDV oﬀers a unique opportunity to determine what
these are and how they aﬀect the functional roles of the
HDV proteins.
Phosphorylation [32,33], acetylation [34], methylation
[35], prenylation [36] and several other post translational
modiﬁcations of the HD antigens [37–39] have been
shown to orchestrate the life cycle of the virus. Diﬀerent
phosphorylation patterns of the small and large HD-Ag
account for their distinct biological functions [32] and
phosphorilated SHD-Ag increases replication from
antigenomic to genomic RNA [33]. Acetylation and
deacetylation of HD-Ag may provide a molecular switch
for the synthesis of the diﬀerent RNA species [34], and
interactions with the multifunctional transcription fac-
tor YY1 and its associated acetyltransferase selectively
modulates replication of the genomic and antigenomic
forms [39]. Methylation at arginine residues regulates
the subcellular localization and also RNA replication
[35]. Farnesylation of the LHD-Ag is essential to target
this protein to cellular membranes containing the
HBsAg in order to trigger viral assembly [40]. More
intriguing, the participation of HDV proteins in the reg-
ulation of cellular gene expression could trigger HDV-
related liver damage. It was reported that isoprenylation
of LDH-Ag regulates Transforming-Growth Factor -b-
induced signal-transduction and through this mecha-
nism may induce liver ﬁbrosis [41].2. Epidemiological and clinical impact
Indirect antibody assays for the diagnosis of HDV
became generally available at the beginning of the
1980s, prompting worldwide studies on the epidemiol-
ogy and medical impact of the infection. Molecular
assays for the direct measure of HDV–RNA in serum
were developed but have not been made commercially
available and are limited to specialized laboratories
only; the current PCR assays are speciﬁc and have a sen-
sitivity threshold of 10–100 copies of the HDV genome
[42,43], per ml of serum.
Surveys in the 1980s showed that HDV is endemic
worldwide, though with prevalences and patterns of
infection varying in diﬀerent areas; globally the number
of HDV carriers was estimated at 15,000,000 at that
time [44]. Medical scrutiny conﬁrmed that CHD usually
runs a severe and progressive course [45]. The prototype
patient with CHD carried the HBsAg in blood, had ele-
vated ALT, a liver biopsy exhibiting aggressive hepatitis
but no markers of HBV replication; the discrepancy
between a ﬂorid HBsAg-disease and the lack of HBV
synthesis provided the best harbinger to the suspicion
of an underlying HDV infection [46]. However, in epide-
miological pockets as far away as the Greek island of
Archangelos and Paciﬁc Samoa, HDV caused no or
insigniﬁcant disease, indicating that the course of
HDV infections may span a clinical spectrum ranging
from asymptomatic carriage of the virus to very severe
disease [47].
A factor that may inﬂuence the course of disease is
the genotype of the HDV. Currently this virus is divided
into eight major genotypes diﬀering as much as 40% in
nucleotide sequence [48]. Genotype I is the most fre-
quent worldwide and has variable pathogenicity. In a
study from Taiwan CHD patients infected with geno-
type I HDV had a lower remission rate and more
adverse outcomes [49] than those with genotype II
HDV. Genotypes II and IV were found in East Asia
causing relatively mild disease [50]; however, a genotype
II b variant isolated from HDV patients from the
Miyako Island, Okinawa (II b-M) was associated with
greater progression to cirrhosis then the II b genotype
prevalent in Taiwan [51]. Genotype III was associated
with the genotype F of HBV and fulminant hepatitis
in South America [46]. While the genotype of HBV does
not seem to aﬀect the interaction of HBsAg with HDV,
the genotype of HDV may inﬂuence the eﬃciency of
assembly with the HBsAg into virions. Aminoacid
sequence variations in HBsAg expressed by naturally
occurring variants of HBV diminished the assembly eﬃ-
ciency of genotype II and IV of HDV but not of geno-
type I [52]; the more eﬃcient interactions between
genotype I of HDV and HBV, might play a role for
the wide distribution of HDV I in the world.
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signiﬁcantly in Europe, consistent with the hypothesis
that the virus was discovered at the time of a major epi-
demic that has been brought under control by now [53].
Sequential surveys in Italy, each one in several hundreds
of HBsAg carriers with liver disease documented an
anti-HD rate of 24.6% in 1983 [54], of 23% in 1987
[55], of 14% in 1992 [56] and of 8.3% in 1997 [57]. Con-
sistent declines in the prevalence of HDV were also
reported in Spain [58], Taiwan [59] and Turkey [60]. In
Turkey the overall prevalence of anti-HD in HBsAg car-
riers with liver disease and in those with cirrhosis dimin-
ished, respectively, from 31% to 11% and from 43.3% to
24% in the period 1980–2005.
Along with the decline in the circulation of HDV, the
clinical scenario of hepatitis D has also changed. While
the majority of hepatitis D patients observed in Italy in
the 1980s had a ﬂorid chronic active hepatitis, and cir-
rhosis was seen in fewer than 20% of cases, by the end
of the 1990s, the proportion of cirrhosis residual to
burnt-out inﬂammation had increased to 70% [61,62].
The common denominator in the control of HDV is
the spectacular control of HBV achieved in the last 15
years, which is depriving the defective HDV of the
HBV network necessary to propagate its infection [63].
By contrast, it is unlikely that HDV is being brought
under control in the many HDV hyperendemic areas
where HBV remains still unchecked, and a signiﬁcant
presence of hepatitis D has been reported in the last
three years from Pakistan [64], India [65], Mongolia
[66], Iran [67,68], Vietnam [69], Tajikistan [70],
Tunisia [71], Mauretania (Francoise Lunel, personal
communication).
The dramatic decline of HDV in Europe at the end
of the 1990s has raised the hope that in this area hep-
atitis D would soon be cancelled from the list of com-
municable diseases [57]. This perspective, however, now
appears too optimistic and certainly premature. In
London [72], the prevalence of HDV has remained sta-
ble (around 8.5%) between 2000 and 2006; most HDV
patients were from Southern or Eastern Europe, Africa
and the Middle East, and their mean age was 36 years.
In Hannover [73], the prevalence declined from 18.6%
in 1992 to 6.8% in 1997 but no further decrease was
recorded thereafter; from 1999 onwards, between 8%
and 14% of the HBsAg carriers were positive for
anti-HD, the majority were immigrants from Turkey
and the ex-Soviet Union. In France [74] there is still
a residual HDV population represented mostly by Afri-
can immigrants; within this epidemiological niche the
infection seems to be increasing. In the most recent sur-
vey of 1179 HBsAg carriers conducted in Italy in 2006,
the prevalence of anti-HD was 8.1% [75], similar to the
prevalence found in 1997, suggesting that the decline of
HDV has not continued.Thus the consistent reservoir of HDV remaining in
Europe is sustained by two diﬀerent pools of HDV-
infected patients. One is composed of the residual ageing
domestic pool that survived the brunt of the hepatitis D
epidemic in the 1970–1980s. The other is made up by a
population of young patients with recent HDV infec-
tions migrating to Europe from areas where HDV
remains endemic [76]. HDV may be returning not only
by import but also by spreading in loco. Immigrants
from many parts of the world are also heavily infected
with HBV and segregation of these HBsAg carriers into
metropolitan, overcrowded ghettos may locally restore a
dense HBsAg network, providing a fertile terrain to the
secondary spreading of HDV.3. Therapy; beyond Interferon, the problems and the
perspectives
Alfa-Interferon was ﬁrst used in CHD 25 years ago
and still remains the only available treatment. Results,
however, are far from optimal [77]. Standard treatment
given for one year achieves remission of CHD in about
20–25% of the patients, but the rates of HDV–RNA
clearance are distinctly lower. Somewhat better results
are obtained with a more aggressive schedule and higher
dosage of IFN; liver chemistry may ameliorate in about
50% of the patients while on therapy, yet again the clear-
ance of HDV [78] is sustained only in a minority. Pro-
longing therapy up to two years did not increase the
rate of sustained response over 1 year of treatment [79].
Peg-IFN may be more beneﬁcial; in a study of CHD
patients treated with Peg IFN alfa 2b 1.5 lg/kg weekly
for 12 months, 6 of 14 (43%) achieved a sustained clear-
ance of serum HDV–RNA [80]. However, in two other
groups of patients treated with the same Peg-IFN, a sus-
tained viral response was obtained only in 17% [81] and
21% of the patients [82]. The small number of patients
included in all treatment series makes it diﬃcult to dis-
criminate a true therapeutic advantage of IFN from a
more benign spontaneous course of the disease. Though
there are anecdotal reports of resolution of HBV/HDV
infections and even of ﬁbrosis in HDV patients treated
with IFN [78], no controlled study has been carried
out to determine whether IFN induces a signiﬁcant
long-term eﬀect; of note disease resolution may occur
in the natural history of HDV infections and in a fol-
low-up over many years the rate of spontaneous clear-
ance of the HBsAg was higher in HDV-positive than
negative carriers of the HBsAg [83]. Treatment failures
might result from the interference of HDV with IFN-
alfa intracellular signalling; in HDV-transfected hepa-
toma cells the blocking of the activation of Tyk2 by
HDV resulted in the selective impairment of activation
and translocation to the nucleus of STAT1 and STAT2
[84].
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repressed. Nevertheless Famciclovir, Lamivudine and
Adefovir, which are inactive against HDV but active
against the helper HBV, were used in monotherapy or
in combination with IFN, in an attempt to further
diminish the replication level of HBV and totally deprive
the defective HDV of the helper eﬀect. Neither one nor
their combination with IFN, where more eﬃcacious
than IFN [77,85]. The problem confronting HDV ther-
apy is that there is no speciﬁc enzymatic function to tar-
get, such as the polymerases and proteases of HBV and
HCV. It should be considered that HDV depends on the
HBsAg and not on HBV replication, therefore its syn-
thesis is not inﬂuenced by the level of HBV-DNA in
serum; the secretion of HDV in vitro [86] and the levels
of HDV–RNA in vivo [87] are directly correlated to the
amount of serum HBsAg, not to the titer of HBV-DNA.
Potential targets to therapy are oﬀered by the process of
HD virion assembly. On the HBV side, this requires the
integrity of critical regions of the HBsAg. Deletion of
residues 24–28 on the small HBsAg led to an envelope
mutant deﬁcient for production of HD virions [88] and
the interactions of the LHD-Ag with HBsAg were
ablated by the substitution of phenylalanine for trypto-
phan at positions 196, 199 or 201 of the small HBsAg
[89]. Likewise, mutations or conformational changes in
cysteines on the antigenic loop of the HBsAg (which
bears the conserved a determinant and is involved in
HDV infectivity) created a block to the entry of HDV
into cells [90]. This evidence would suggest that there
are several sites on the HBsAg central to HDV matura-
tion, the disruption of which may oﬀer a target to anti-
viral therapy. Interestingly, lamivudine-induced
mutations in the polymerase region, which confer
HBV resistance to this therapy, are associated with
changes in the overlapping envelope gene products; a
change in SW 196 L/S of the small HBsAg, carried by
mutation M 204 I in the reverse transcriptase of HBV,
was found to inhibit the secretion of HDV particles in
cell cultures, suggesting that lamivudine therapy
may indirectly abrogate an underlying HDV infection
[91].
On the HDV side, critical to the interaction of LHD-
Ag with the HBV envelope protein is farnesylation (pre-
nylation), of the last four aminoacids Cys-Arg-Pro-Gln-
COOH on the LHD-Ag (so-called CXXX box; C for
cysteine, X for any amino-acid) [92]. By preventing the
association of the HDV ribonucleoprotein with the
HBsAg and, therefore, virion assembly, disruption of
prenylation might form the basis of a new therapeutic
strategy against HDV; experiments in vitro have shown
that HDAg prenylation can be inhibited by the prenyla-
tion inhibitor BZA-5B and in vivo the prenylation inhib-
itors FTI – 277 and FTI – 2153 were highly eﬀective at
clearing HD viremia in a mouse model of HDV infec-
tion [93].4. Conclusions and perspectives
Most rewarding were the studies on the nature of
HDV, which have unravelled an unsuspected maze of
viral and cellular interactions induced by a novel human
virus, unique in size, in possessing a ribozyme, in repli-
cating by a rolling circle mechanism, in redirecting to
its advantage the cellular replicative machinery.
Paradoxically, the most outstanding feature of this
highly pathogenic agent is currently attracting attention
as a potential therapeutic tool in the development of
gene inactivation systems based on the direct targeting
of RNAs. As the only catalytic cleaving RNAs in
humans, the HDV ribozymes function properly in the
low-ionic environment of human cells, are more stable,
have a longer half-life than the other non-human ribo-
zymes, and should not be recognized by the immune sys-
tem as an external, invading RNA [94].
The adaptation to the human cell environment makes
HDV ribozymes suitable RNA silencing tools and strat-
egies are being developed for their therapeutic use in the
inhibition of viral activity, cancer growth and inherited
genetic diseases.
The circulation of HDV and its clinical impact have
greatly diminished in Europe, decreasing interest in its
infection. To the point that the sensitive HDV–RNA
assays developed in the last years have not become
widely available and that testing of HBsAg carriers for
HDV is often neglected even in high-rank laboratories.
This was the case in London [72], where a number of
metropolitan viral laboratories were contacted and none
of them routinely tested HBV-infected patients for anti-
HD.
HDV remains a major health problem in the many
underdeveloped areas of the world where HBV is uncon-
trolled; the price extolled by globalisation and the
increasing migratory ﬂuxes is the reconstitution of a
HDV reservoir and the recapitulation of ﬂorid HDV dis-
ease among immigrants to Europe. Awareness of this
new threat should enforce more vigilance in order to
provide accurate contemporary scenarios of HDV and
plan adequate prevention.
Therapy of hepatitis D remains the most unsolved
business. It is discouraging that the therapy available
today is not diﬀerent from the limited IFN treatment
attempted more than 20 years ago. The problem is formi-
dable asHDVhas no enzymatic proteins to be targeted by
conventional antiviral therapy. However, the lesson that
antiviral drug therapy improves with the increase of the
knowledge of the replication mechanisms of the virus,
augers well also for the prospects of HDV therapy. The
accelerated progress in the understanding of the molecu-
larmechanisms ofHDV, in particular of theHBsAg inter-
actions between the large HD antigen and the HBsAg in
the assembly of the HD virion, may provide a potential
therapeutic target, unconventional as the HDV itself.
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